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Background: Advanced hepatocellular carcinoma (HCC) patients undergo significant tumor growth and metastasis.
Here, we investigated bufalin for treating HCC, which exhibits anti-tumor activities in many tumor cell lines.
Method: In our experiment, HCCLM3-R cells were injected into nude mice to form subcutaneous human HCC
tumors that were implanted into the liver to establish orthotopic transplantation tumor models. Bufalin was injected
intraperitoneally at 1 or 1.5 mg/kg. LY294002 (100 mg/kg), a potent inhibitor of Akt which reduced the levels of
pAkt in HCCLM3 cell lines, was injected intraperitoneally into one group thrice weekly. The control was injected
with an equal volume of saline. Morphological alterations were evaluated in the liver and lung by stereomicroscopy,
the apoptotic rate was measured by TUNEL staining, and expression of AKT/GSK3β/β-catenin/E-cadherin signaling
pathway-related proteins was detected by immunohistochemistry (IHC) and western blot analysis.
Results: These results suggested that the sizes and qualities of orthotopic transplanted tumors as well as
pulmonary metastasis decreased markedly at the highest bufalin dose compared with that in the control.
Orthotopic transplanted tumor tissues were necrotic in bufalin-treated groups and the apoptotic cell number was
markedly higher at the highest bufalin dose compared with that in the control. Certain changes of expression of
AKT/GSK3β/β-catenin/E-cadherin signaling pathway-related proteins were in tumor tissues, which were related to
the bufalin dose. Similar results were observed in the LY294002-treated group.
Conclusion: Based on the above, one can draw conclusions that bufalin has significant anti-tumor activities and
reduces the metastatic potential in an orthotopic transplantation tumor model of human HCC. Inhibition of AKT/
GSK3β/β-catenin/E-cadherin signaling pathways by bufalin may show therapeutic effects in advanced HCC patients.
Keywords: Hepatocellular carcinoma, Pulmonary metastases, Orthotopic transplantation tumor models, AKT/GSK3β/
β-catenin/E-cadherin signaling pathwaysBackground
Hepatocellular carcinoma (HCC) is the most common
primary liver tumor and the third highest cause of cancer-
related deaths worldwide (696,000 deaths, 9.2%) [1]. The
high mortality rate is related to poor early diagnosis because
of a lack of observable symptoms, as well as the aggressive-
ness of the disease and limited therapeutic options. Thus,
most HCC patients are diagnosed with advanced disease
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unless otherwise stated.times of about 6–8 months [2]. However, patients that
undergo surgical resection or liver transplantation at an
early stage of HCC have 5-year overall survival rates of
30–40% [3] and 61–89%, respectively [4]. The short
survival time of HCC patients is associated with tumor
initiation, progression, and metastasis. Recently, the
phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)
signaling pathway has been found to play an essential
role in cancer cell proliferation, survival, metabolism,
motility, and invasion, thereby facilitating the formation
of clinical metastases [5]. The pro-survival activity of
the PI3K/Akt signaling pathway has been investigated
in great detail in human physiology and disease. Previ-
ous studies have demonstrated that this signaling axis
is actively engaged in metastatic cancer cells [6]. AKTLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mesenchymal transition during tumorigenesis [7]. Nude
mouse experiments have shown that suppression of the
PI3K/AKT signaling pathway can inhibit tumor growth,
reduce angiogenesis, and improve the tumor micro-
environment [8].
Bufalin is the major bioactive component of venenum
bufonis with antitumor activity, which is a traditional
Chinese medicine obtained from the skin and parotid
venom glands of toads [9]. In previous studies, bufalin
has been demonstrated to induce apoptosis in gastric
cancer MGC803 cells and oral cancer CAL 27 cells by
inhibition of the AKT signaling pathway [10,11]. Our
previous in vitro studies have shown that the mecha-
nisms underlying the antitumor effects of bufalin in
hepatoma cells appear to be mediated by AKT/GSK3β/
β-catenin/E-cadherin signaling pathways [12].
The present study used an orthotopic human HCC model
with high metastatic potential in nude mice [13]. We ob-
served the effects of bufalin on inhibition of HCC growth
and metastatic potential and explored the mechanism of the
AKT signaling pathway in the nude mouse model.Methods
Animals
Male athymic BALB/c nu/nu mice (18–20 g, 5 weeks old)
were obtained from the Shanghai Institute of Materia
Medica, Chinese Academy of Science. All mice were han-
dled according to the recommendations of the National
Institutes of Health Guidelines for Care and Use of
Laboratory Animals. The experimental protocol was
approved by the Shanghai Medical Experimental Animal
Care Committee.HCC cell line
Stable red fluorescent protein-expressing HCCLM3
(HCCLM3-R) cells infected with a lentivirus containing
full-length cDNA of red fluorescent protein were used in
this study [13].The HCCLM3-R cells were maintained at
37°C with 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS).Treatments
Bufalin (purity >98%) was purchased from Shanghai Tauto
Biotech Co., Ltd. (Shanghai, China) and dissolved in etha-
nol at a concentration of 0.2 g/L. LY294002 was purchased
from Cell Signaling Technology (Beverly, MA, USA) and
diluted in phosphate buffered saline (PBS) at a concentra-
tion of 13 g/L. Reagents were sterilized by passing through
a 0.22 μm filter and stored at 4°C.Metastatic orthotopic tumor model in nude mice
A metastatic model of human HCC in nude mice using
HCCLM3-R cells was employed for this study [13]. Briefly,
HCCLM3-R cells (5 × 106) were injected subcutaneously
into the upper left flank region of nude mice. When the
subcutaneous tumors reached approximately 1 cm in
length (approximately 4 weeks after injection), they were
removed, minced into small pieces of equal volume
(1.5–2 × 2 × 2 mm3), and transplanted into the livers of
24 nude mice. The animals were randomly divided into
four groups (n = 6). Based on the literature [14,15] and
the results of our preliminary experiments, we used
physiological saline to dilute the bufalin and LY294002.
Bufalin was intraperitoneally injected into two groups
of mice at doses of 1 mg/kg and 1.5 mg/kg from day 8
to 38, and LY294002 was intraperitoneally into one
group of mice at a dose of 100 mg/kg thrice weekly as a
positive control. The control group was injected with
an equal volume of saline (0.15 ml) from day 8 to 38.
All mice were sacrificed and weighed on day 39.
Analysis of tumor necrosis and apoptosis
Paraffin-embedded sections were prepared for hematoxylin
and eosin (H&E) staining. Tumor tissue necrosis was de-
termined by comparing the surface of necrotic areas with
that of the whole tumor. Apoptosis was determined using
a terminal transferase dUTP nick end labeling (TUNEL)
assay kit according to the manufacturer’s protocol. A posi-
tive sample contained 25 positively stained cells in every
100 tumor cells calculated randomly from five high magni-
fication (400×) fields for each specimen.
Detection of metastasis by fluorescence microscope and
H&E staining
Tumors were excised, weighted, and the largest (a) and
smallest (b) diameters were measured to calculate the
tumor volume (V) with the formula: V = ab2/2 [16]. And
the inhibition rates of tumors with the formula: inhibition
rates (%) = (NS tumor weight (g)-medication tumor weight
(g))/NS tumor weight (g) × 100%). The lungs and mesen-
teries were also excised, red fluorescent protein-positive
metastatic foci were analyzed by fluorescence microscopy,
and the integrated absorbance was quantitated by Image-
Pro Plus software as described previously [17]. Then,
orthotopic tumors and lungs were fixed with 10% buffered
formalin and embedded in paraffin. Serial sections of pul-
monary metastatic nodules and mesenteries were cut at 5
μm intervals and stained with H&E [12].
Immunohistochemical staining for phosphorylated
(p)-AKT, AKT, p-GSK3β, GSK3β, β-catenin, E-cadherin,
MMP-2, and MMP-9
To assess the distribution of p-AKT and AKT(purchased
from Cell Signaling Technology, Inc. (Beverly, MA, USA)),
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MMP-9 (purchased from Epitomics, Inc. (Burlingame, CA,
USA)), we stained sections with rabbit anti-p-Akt (1:250),
anti-Akt (1:100), anti-pGSK3β (1:100), anti-GSK3β (1:200),
anti-β-catenin (1:200), anti-E-cadherin (1:200), anti-MMP-2
(1:150), and anti-MMP-9 (1:100) antibodies. A rabbit anti-
rat fluorescein isothiocyanate-conjugated antibody (1:100)
was applied as the secondary antibody. All sections were in-
dependently assessed by two board-certified pathologists
who were blinded to the experiment. For negative controls,
primary antibodies were replaced with PBS. Positive sam-
ples contained 25 positively stained cells in every 100 tumor
cells calculated randomly from five high magnification
(400×) fields for each specimen. After immunohistochemis-
try (IHC), morphometrical analysis was conducted with the
Imageproplus color image analysis system. One-hundred
positive cells in each positive sample were chosen randomly
under 200× and 400× magnification. Then, the average op-
tical density (AOD) and integral optical density (IOD) of
positive granules were detected as relative amounts of
p-AKT, AKT, p-GSK3β, GSK3β, β-catenin, E-cadherin,
MMP-2, and MMP-9 in cells. Positive cells in HCC xeno-
grafts were calculated as follows: AOD= IOD/total sample
area [18].
IHC staining was also scored as follows: IHC 0 (com-
pletely negative), IHC 1+ (faint membranous or cytoplas-
mic positivity), IHC 2+ (moderate, smooth membranous or
cytoplasmic positivity), IHC 3+ (strong, more than 30%
tumor cells with circumferential membranous or intense,
granular cytoplasmic positivity ) in more than 10% of tumor
cells. Scoring was performed by two pathologists [19].Western blotting analysis
Fresh tumor tissues in RIPA lysis buffer containing 1 ug/
ml PMSF were manually homogenized on ice using a glass
homogenizer, then centrifuged at 10000 g for 10 min to
remove celluar and nuclear debris. The protein concentra-
tions were determined with the BCA protein assay, and
equal amounts of protein were subjected to 12% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). After electrophoresis, proteins were transferred
onto polyvinylidene difluoride membranes (PVDF). The
membranes were blocked for 1 hour at room temperature
in 5% nonfat dry milk in Phosphate Buffered Saline
with Tween-20 (PBST), followed by overnight incuba-
tion at 4°C with primary antibodies. The membranes
were washed and then incubated with a peroxidase conju-
gated secondary antibody for 1 hour at room temperature.
Blots were detected through chemiluminescence substrate
(ECL plus) and acquired by digital images.Primary anti-
bodies used include rabbit anti-pAkt (1:100), anti-Akt
(1:1000), anti-pGSK3β (1:10000),anti-GSK3β (1:5000),
anti-β-catenin (1:5000), anti-E-cadherin (1:5000), anti-MMP-2 (1:1000), anti-MMP-2 (1:1000) and GAPDH
(1:1000).
Statistical analyses
Statistical analyses were performed with IBM SPSS Statis-
tics 19 for Windows. Quantitative variables were analyzed
by analysis of variance and expressed as the mean ± SD.
Results were considered statistically significant at P < 0.05.
Results and discussion
Bufalin inhibits tumor growth but has no effect on nude
mouse survival
After 4 weeks of treatment, high-dose bufalin-treated mice
had smaller tumor volumes compared with those of mice
in the control group (712.88 ± 212.12 mm3 vs. 1379.75 ±
741.48 mm3, P < 0.05) and lower tumor weights compared
with those of mice in the control group (1.10 ± 0.23 g vs.
1.93 ± 0.45 g, P < 0.01). However, there were no significant
differences between low-dose bufalin-treated mice and the
control group in terms of their tumor volumes (1174.69 ±
692.42 mm3 vs. 1379.75 ± 741.48 mm3, P > 0.05 ) and
weights (1.65 ± 0.60 g vs. 1.93 ± 0.45 g, P > 0.05).
LY294002-treated mice had the smallest tumor volumes
(438.35 ± 303.37 mm3) and lowest tumor weights (0.76 ±
0.23 g), which were not obviously different from those in
the high-dose bufalin-treated group (P > 0.05) (Figure 1A–
C). The inhibition rates of tumors were 13.51 ± 1.35% in
low-dose bufalin-treated mice, 46.27 ± 2.06% in high-dose
bufalin-treated mice, and 66.83 ± 1.40% in LY294002-
treated mice (Figure 1D). On the other hand, pre- and-
post-treatment variation of nude mouse body weights
among the four groups showed no significant differences.
Also during the process, appetites and behaviors of these
four groups nude mouse were much the same. In addition,
there were no treatment-related deaths (Figure 1E). Col-
lectively, bufalin inhibited tumor growth in nude mice in a
dose-dependent manner but had no effect on nude mouse
survival.
Orthotopic transplanted tumor tissues undergo necrosis
and apoptosis induced by bufalin treatment
The in situ transplanted tumors exhibited relatively regu-
lar round or oval shapes with complete or incomplete cap-
sules. Compared with the control, mice treated with
bufalin had a significantly smaller tumor volume. H&E
staining revealed that the nuclei of the liver cancer cells
were large with an oval shape and contained more chro-
matin. Binucleated cells were large and clearly visible with
more free ribosomes and more pathological karyokinesis.
Severe necrosis was mainly observed in high-dose bufalin-
treated and LY294002-treated groups, whereas there was
moderate necrosis in the low-dose bufalin-treated group
and mild necrosis in the control group. Tumor cells with
less cytoplasm were observed in high-dose bufalin-treated
Figure 2 Orthotopic transplanted tumor tissues undergo necrosis and apoptosis induced by bufalin treatment. (A) Detection of transplanted
tumors in control (NS), low-dose bufalin-treated (BF1), high-dose bufalin-treated (BF2), and LY294002-treated (LY) groups by fluorescence microscopy
and necrotic tumor tissues by H&E staining (×400). (B) Positive TUNEL staining in the nuclei of control (NS), low-dose bufalin-treated (BF1), high-dose
bufalin-treated (BF2), and LY294002-treated (LY) groups (×200 and ×400). (C) TUNEL staining showed different apoptotic rates in control (NS),
low-dose bufalin-treated (BF1), high-dose bufalin-treated (BF2), and LY294002-treated (LY) groups. All data represent the mean ± SD (n = 6).
*P < 0.05 vs. control (NS); †P < 0.01 vs. control (NS).
Figure 1 Bufalin inhibits tumor growth but has no effect on nude mouse survival. (A) Tumor volumes of control (NS), low-dose bufalin-treated (BF1),
high-dose bufalin-treated (BF2), and LY294002-treated (LY) groups by visual inspection. (B) Quantitation of tumor volumes in control (NS), low-dose bufalin-
treated (BF1), high-dose bufalin-treated (BF2), and LY294002-treated (LY) groups. (C) Quantitation of tumor weights in control (NS), low-dose bufalin-treated
(BF1), high-dose bufalin-treated (BF2), and LY294002-treated (LY) groups. (D) Tumor inhibition rates of control (NS), low-dose bufalin-treated (BF1), high-dose
bufalin-treated (BF2), and LY294002-treated (LY) groups. (E) Nude mouse body weights of control (NS), low-dose bufalin-treated (BF1), high-dose bufalin-
treated (BF2), and LY294002-treated (LY) groups. All data represent the mean± SD (n = 6). *P < 0.05 vs. control (NS); †P < 0.01 vs. control (NS).
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control group, including apoptotic signs such as pyknotic
nuclei, chromatin condensation around the edges, and
clefts in the nuclei (Figure 2A). Positive TUNEL staining
was located in the nuclei (Figure 2B). The numbers of
apoptotic cells in control, low-dose bufalin-treated, high-
dose bufalin-treated, and LY294002-treated groups were
63.20 ± 10.33, 107.80 ± 14.20, 146.80 ± 14.20, and 106.20 ±
7.12 per 400× magnification field, respectively (Figure 2C).
Therefore, orthotopic transplanted tumor tissues undergo
necrosis and apoptosis induced by bufalin treatment.
Bufalin inhibits pulmonary metastases
Pulmonary metastases were also significantly inhibited by
bufalin in the HCCLM3-R cell model. Bioluminescence
showed that the pixel numbers of pulmonary metastatic
foci in high-dose and low-dose bufalin-treated mice were
significantly less than those in control mice (512.00 ±
95.83 and 2217.00 ± 475.07 vs. 17937.33 ± 3997.06 per
lung, P < 0.01, respectively). In H&E staining, a decrease
in the cell number of pulmonary metastatic nodules was
found in high-dose and low-dose bufalin-treated groups
compared with that in the control (39.67 ± 3.72 and 68.17 ±
9.47 vs. 112.17 ± 19.05 per lung, P < 0.01, respectively). A
similar trend toward reduction of the pixel number of pul-
monary metastatic foci (356.50 ± 83.29 vs. 17937.33 ±
3997.06 per lung, P < 0.01) and cell number of pulmonary
metastatic nodules (36.33 ± 5.99 per lung, P < 0.01) wasFigure 3 Bufalin inhibits pulmonary metastases. (A) Detection of pulm
dose bufalin-treated (BF2), and LY294002-treated (LY) groups by fluorescen
Detection of intrahepatic, enteric cavity, and abdominal wall tissues by H&E
in control (NS), low-dose bufalin-treated (BF1), high-dose bufalin-treated (B
pulmonary metastatic nodules in control (NS), low-dose bufalin-treated (BF
All data represent the mean ± SD (n = 6). †P < 0.01 vs. control (NS).also observed in LY294002-treated mice with HCCLM3-R
xenografts compared with those in control mice (Figure 3A,
C and D). After exploratory laparotomy and observing the
histological characteristics of the samples, no intrahepatic
dissemination, peritoneal dissemination, or abdominal
lymph node metastasis were found in all four groups of the
HCCLM3-R xenograft model (Figure 3B).
Taken together, analysis of serial lung sections indicated
significant inhibition of pulmonary metastases in bufalin-
treated mice.
Bufalin-treated tumors exhibit changes consistent with
the AKT/GSK3β/β-catenin/E-cadherin signaling pathway in
nude mice
On day 39 after treatments, control, low-dose bufalin-
treated, high-dose bufalin-treated, and LY294002-treated
hepatomas were subjected to IHC. First, treatment of
HCCLM3-R xenografts in nude mice with bufalin inhibited
Akt phosphorylation. High-dose and low-dose bufalin-
treated groups had lower average Akt phosphorylation
levels compared with those in the control group. The
LY294002-treated group had the lowest Akt phosphoryl-
ation levels. In addition, bufalin treatment enhanced total
GSK3β expression and inhibited GSK3β serine 9 phos-
phorylation in a dose-dependent manner. Total GSK3β ex-
pression of tumors was IHC 1+ in low-dose bufalin-treated
mice, IHC 2+ in high-dose bufalin-treated mice and
IHC 0 in the control. Furthermore, GSK3β serine 9onary metastases in control (NS), low-dose bufalin-treated (BF1), high-
ce microscopy and necrotic tumor tissues by H&E staining (×400). (B)
staining (×200). (C) The pixel numbers of pulmonary metastatic foci
F2), and LY294002-treated (LY) groups. (D) The cell numbers of
1), high-dose bufalin-treated (BF2), and LY294002-treated (LY) groups.
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and high-dose bufalin-treated groups was IHC 3+, IHC
2+, and IHC 1+, respectively. The reduction of p-Akt
expression appeared without any change in the total
amount of Akt (similar protein levels among the four
groups). Moreover, expression of p-GSK3β was signifi-
cantly down-regulated with the increase in the total
amount of GSK3β by bufalin treatment. Both total
GSK3β and p-GSK3β showed analogous expression in
the LY294002-treated group (Additional file 1: Figure
S1A and B).
Second, the highest levels of β-catenin at the cell mem-
brane were observed in the control group, which de-
creased with bufalin treatment in low-dose and high-dose
bufalin-treated groups. The LY294002-treated group had
the lowest β-catenin protein level.
Third, untreated tumors showed typical membranous E-
cadherin expression at cell-cell contacts, and E-cadherin-
positive cells were localized in central tumor areas. IHC
exhibited weak staining of E-cadherin in the control
group. In contrast, bufalin-treated groups showed an over-
all increase of E-cadherin expression. The LY294002-
treated group had the highest E-cadherin protein level
(Additional file 1: Figure S1C).
Finally, MMP-2 protein levels were significantly down-
regulated and expression of MMP-9 protein also decreased
in bufalin-treated groups compared with that in the con-
trol. High-dose bufalin-treated mice had lower MMP-2
and MMP-9 protein levels compared with those in the
control and low-dose bufalin-treated mice. LY294002-
treated mice had the lowest MMP-2 and MMP-9 protein
levels (Additional file 1: Figure S1D).
In summary, changes in the expression of numerous im-
portant regulatory proteins (Additional file 1: Figure S1E)
in the AKT/GSK3β/β-catenin/E-cadherin signaling path-
way occurred in a dose-dependent manner by treatment
with bufalin.
Bufalin was able to modulate protein expressions
consistent with AKT/GSK3β/β-catenin/E-cadherin signaling
pathway by western blot analysis
On day 39 after treatments, control, low-dose bufalin-
treated, high-dose bufalin-treated, and LY294002-treated
hepatomas were subjected to western blot analysis. Bufalin
significantly downregulated the expression of pAKT in
HCCLM3-R cells without affecting the total protein levels
of AKT. Also, bufalin significantly suppressed the phos-
phorylation of GSK protein and increased GSK3β protein
activation. Also, bufalin significantly suppressed β-catenin
protein. Then we further investigated the downstream
molecular actions of E-cadherin after the inhibitory β-
catenin protein. We found that bufalin significantly in-
creased E-cadherin expression in HCCLM3-R cells. The
association between MMP expression and the invasiveactivity of various types of cancer provided by the loss of
E-cadherin had been well documented. Bufalin can regu-
late the expression of MMP-9 and MMP-2 at the tran-
scriptional level in hepatoma cells. Furthermore, bufalin
inhibited the expression of pAKT, AKT, pGSK3β, GSK3β,
β-catenin, E-cadherin MMP-2 and MMP-9 in HCCLM3-
R in a dose-dependent manner. On the other hand,
LY294002, a potent inhibitor of AKT, acted on the levels
of pAKT, AKT, pGSK3β, GSK3β,β-catenin, E-cadherin
MMP-2 and MMP-9 observed in mice with HCCLM3-R
xenografts hepatomas display similar trends to bufalin-
treated group (Figure 4).
In short, bufalin was able to modulate protein expressions
consistent with AKT/GSK3β/β-catenin/E-cadherin signaling
pathway in HCCLM3-R cells by western blot analysis
Conclusions
HCC is the most common primary liver tumor and is de-
fined as a high-mortality disease [1]. Metastasis begins
with cell outgrowth from a primary tumor, followed by in-
vasion and survival in stromal tissues, which is responsible
for 90% of cancer patient deaths [20]. Therefore, it is par-
ticularly important to improve patient survival to control
the tumor-initiating and metastatic properties of HCC.
Currently, there are no reports of the influence of bufa-
lin on the stage and metastatic potential of HCC in vivo.
Therefore, to study tumor growth and pulmonary metas-
tases under exposure to bufalin, we established orthotopic
transplantation tumor models of human HCC in nude
mice using HCCLM3-R cells.
We found that doses of 1 and 1.5 mg/kg bufalin inhibited
tumor growth, including reductions of the tumor volume
and weight, and increased the tumor inhibition rate, which
was more apparent at the highest dose of bufalin. In
addition, bioluminescence showed clear dose-dependent
inhibition of pulmonary metastasis in bufalin-treated mice.
The number of pixels indicating pulmonary metastatic foci
showed a significant decrease in the high-dose bufalin-
treated group. Combined with our previous in vitro results
concerning the effects of inhibiting hepatoma cell prolifera-
tion, migration, invasion, and adhesion using bufalin [12],
we conclude that bufalin has the same anti-tumor effects
in vitro and in vivo.
Our previous study also showed that bufalin inhibits
expression of p-AKT in human hepatoma cells in a time-
dependent manner [12]. Therefore, in this study, we inves-
tigated the effect of bufalin on AKT expression in vivo.
Bufalin-treated groups had lower p-AKT levels than those
in the control group, and the lowest level of p-AKT was
observed in the high-dose bufalin-treated group. On the
other hand, there were no obvious changes in total protein
levels of AKT among the groups. Therefore, the change of
p-AKT levels might be related to tumor growth and the
pulmonary metastatic potential of HCC in the nude mouse
Figure 4 Bufalin can modulate protein expressions consistent with AKT/GSK3β/β-catenin/E-cadherin signaling pathway by western
blot analysis. (A) Protein levels and quantitative analysis of pAKT, AKT, pGSK3β and GSK3β were analyzed by western blotting. (B) Protein levels
and quantitative analysis of β-catenin and E-cadherin were analyzed by western blotting. (C) Protein levels and quantitative analysis of MMP2 and
MMP9 were analyzed by western blotting. All data represent the mean ± SD (n = 6). *P < 0.05 vs. control (NS); †P < 0.01 vs. control (NS).
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variety of human cancers by elevation of Akt activity that
is determined by p-AKT expression. Activated AKT
plays critical roles in metastasis, including escape of the
cells from the tumor environment, activation of cell
proliferation, inhibition of apoptosis, and initiation of
angiogenesis [21].
One of the major downstream effectors of Akt is GSK3β,
a multifunctional serine/threonine kinase. GSK3β levels
may be regulated by bufalin treatment, which requires fur-
ther exploration. Our study showed that p-GSK3β expres-
sion was significantly down-regulated, while total GSK3β
increased by bufalin treatment. Upon Akt activation, Akt
inactivates GSK3β by initiating its phosphorylation at
serine 9 and vice versa [22], which supports our results.
GSK3β also regulates various cellular functions such as cell
survival and cell-fate specification, and participates in nu-
merous signaling pathways linked to diverse physiological
processes and pathological conditions [23]. It is well known
that GSK3β negatively regulates the classical Wnt signaling
pathway by phosphorylation of β-catenin, and activation of
GSK3β induces ubiquitin-dependent degradation of β-
catenin [24]. Our previous in vitro study showing the loss
of nuclear β-catenin accumulation by bufalin treatment in-
dicates that it can modulate switching between membrane-
and nuclear-associated β-catenin [12]. In this study,
considering the relationship between GSK3β and β-catenin
expression, we investigated β-catenin levels and found a
significant decrease of β-catenin levels in bufalin-treated
groups. Therefore, our in vitro and in vivo studies have
confirmed a decrease of β-catenin levels by rapid proteo-
lytic degradation after its phosphorylation by GSK3β, and
an enhancement of activated GSK3β levels by bufalintreatment. Many studies have indicated that the hall-
mark of β-catenin signaling in normal and neoplastic
tissues is nuclear translocation, and activated GSK3β
decreases nuclear β-catenin accumulation and tran-
scriptional activity, suggesting its potent inhibitory
function in Wnt/β-catenin signaling [25].
β-Catenin is a key component of E-cadherin-mediated
cell-cell adhesion that is predominantly associated with the
cytoplasmic domain of E-cadherin at neighboring cell junc-
tions in normal epithelial cells [26]. Immunohistochemical
staining exhibited no staining of E-cadherin in the control
group, whereas bufalin-treated groups showed weak in-
crease of E-cadherin expression. This phenomenon is re-
lated to the proposed mechanism of the AKT signaling
pathway involving β-catenin. Our western blot analysis in-
dicated noticeable changes of tumor β-catenin levels in the
HCCLM3-R cell line and the reduction of β-catenin ex-
pression significantly increases E-cadherin expression.
Therefore, our results suggest that bufalin inhibits tumor
growth and reduces pulmonary metastases in orthotopic
transplantation tumor models of human HCC in nude
mice, and the underlying mechanism is partly mediated by
AKT/GSK3β/β-catenin/E-cadherin signaling pathways.
Further investigation of the pathological changes of
tumor tissues in bufalin-treated groups by H&E staining
and TUNEL assays showed different degrees of necrosis
and apoptosis. These results indicate a close relationship
of the actions of bufalin in the inhibition of HCC growth
and enhancement of necrosis and apoptosis in orthotopic-
transplanted tumor tissue, which are related to regulation
of the PI3K/Akt signaling pathway. Therefore, our results
are consistent with those of previous studies showing that
bufalin induces apoptosis in gastric cancer MGC803 cells
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AKT signaling pathway [10,11].
Our in vivo results revealed that bufalin was able to de-
crease MMP-2 and MMP-9 expression levels in a dose-
dependent manner, whereas our previous in vitro experi-
ments show that bufalin is able to decrease MMP-2 and
MMP-9 expressions in hepatoma cell lines [12]. MMP-2
and MMP-9 are zinc-dependent endopeptidases that play
critical roles in cancer progression and metastasis [27]. Pre-
vious observations show that upregulation of E-cadherin
and a concomitant reduction in MMP-2/MMP-9 levels
might negatively regulate cell proliferation, invasiveness, and
adhesion of K1 papillary thyroid cancer cells and pancreatic
cancer cell lines MIAPaCa-2 and BxPC-3 [28,29]. However,
other studies show that inhibition of the β-catenin pathway
might play a central role in anticancer activities through
modulation of MMPs [30]. Therefore, there has been in-
tense investigation to reduce MMP levels through inhibition
of the β-catenin pathway or upregulation of E-cadherin ex-
pression levels. In future studies, we will clarify the mechan-
ism of MMP-2 and MMP-9 downregulation by bufalin
treatment.
Our study also revealed no differences of nude mouse
survival, body weights, appetites, or behaviors among
bufalin-treated groups and the control, indicating the safety
and efficacy of bufalin treatment. Based on our results, the
next step is large-scale clinical studies of bufalin treatment.
In summary, our results suggest that bufalin exhibits mul-
tiple antitumor effects in orthotopic transplantation tumor
models of human HCC in nude mice, such as inhibition of
tumor growth, leading to tumor tissue necrosis and apop-
tosis as well as a reduction of pulmonary metastasis. The
mechanisms underlying bufalin actions appear to be medi-
ated by AKT/GSK3β/β-catenin/E-cadherin signaling path-
ways. Bufalin is a promising anti-HCC agent, and further
studies should be performed in advanced HCC patients.
Additional file
Additional file 1: Figure S1. Bufalin-treated tumors exhibit changes
consistent with AKT/GSK3β/β-catenin/E-cadherin signaling pathways in
nude mice. (A) Immunohistochemical staining for tumor p-AKT and AKT
protein expressions (×200, ×400, ×1000). (B) Immunohistochemical
staining for tumor p-GSK3β and GSK3β protein expressions (×200, ×400,
×1000). (C) Immunohistochemical staining for tumor β-catenin and
E-cadherin protein expressions (×200, ×400, ×1000). (D) Immunohistochemical
staining for tumor MMP-2 and MMP-9 protein expressions (×200, ×400, ×1000).
(E) Quantitative analysis of expression of p-AKT, AKT, p-GSK3β, GSK3β, β-catenin,
E-cadherin, MMP-2 and MMP-9 protein. All data represent the mean ± SD
(n = 6). †P < 0.01 vs. control (NS).
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